PATENT NO. US 8,501,700 B2 · BSCG CERTIFIED · 185 PUBLISHED STUDIES
The Science of RiboCeine
40 years of research. One patented molecule. One published clinical trial showing a 64.7% increase in glutathione in 28 days. This is the complete scientific case for Cellgevity.
THE INVENTOR
Dr. Herbert T. Nagasawa, Ph.D.
Senior Career Scientist at the US Department of Veterans Affairs. Professor of Medicinal Chemistry at the University of Minnesota. Author of over 185 published papers. Creator of RiboCeine.
“There is not even 1mg of glutathione in Cellgevity. This is intentional — and it is what makes all the difference. The goal was never to supplement glutathione. The goal was to enable your cells to produce their own.”
Dr. Herbert T. Nagasawa, Ph.D.
Inventor of RiboCeine · US Patent No. US 8,501,700 B2
Dr. Nagasawa explains the science behind RiboCeine and why intracellular glutathione production is fundamentally different from supplementation.
About Dr. Nagasawa
THE MECHANISM
Why Oral Glutathione Fails — And Why RiboCeine Does Not
The bioavailability problem with glutathione supplements is not a formulation problem. It is a fundamental molecular biology problem. RiboCeine solves it at the cellular level.
Oral Glutathione Supplements
Ingestion
A glutathione capsule or tablet is swallowed. The glutathione molecule (a tripeptide of glutamate, cysteine, and glycine) enters the digestive system.
Enzymatic Breakdown
Peptidase enzymes in the digestive tract cleave the tripeptide bonds. Glutathione is broken down into its three individual amino acids before it reaches the bloodstream.
Failed Cellular Uptake
Even if trace intact glutathione reaches circulation, cells lack a mechanism to transport intact glutathione molecules across the cell membrane. It cannot enter where it is needed.
Result: No Meaningful Increase
Multiple studies show oral glutathione supplementation does not meaningfully raise intracellular glutathione levels, the only metric that matters for cellular health.
RiboCeine (Cellgevity)
Protected Delivery
RiboCeine bonds D-ribose (a natural sugar) with L-cysteine, forming a stable molecular carrier. This bond protects the cysteine molecule from oxidation and degradation in the digestive tract.
Intact Absorption
The RiboCeine molecule is absorbed intact through the intestinal wall and transported via the bloodstream. The ribose component leverages natural nucleoside transport pathways.
Intracellular Release
Inside the cell, the D-ribose and L-cysteine separate. The cell now has the Cysteine it needs — the rate-limiting precursor for glutathione biosynthesis via the gamma-glutamylcysteine synthetase pathway.
Fresh Glutathione Synthesised
Your cell produces its own fresh glutathione — intracellularly, in the exact form, concentration, and location your mitochondria and cytoplasm require. +64.7% in 28 days.
US Patent No. US 8,501,700 B2
The RiboCeine compound — formally D-ribose-L-cysteine — is a patented molecular technology. The patent covers the synthesis, composition, and method of use of ribose-cysteine conjugates for the purpose of raising intracellular glutathione levels. It was granted to Dr. Nagasawa following decades of research into cysteine prodrug delivery and is exclusively licensed to Max International for use in Cellgevity.
Why Cysteine Is the Key
The Glutathione Tripeptide
Glutathione is composed of three amino acids: glutamate, cysteine, and glycine. Glutamate and glycine are abundant in the body. Cysteine is the bottleneck. Its availability directly determines the rate of glutathione synthesis.
Why Cysteine Is Scarce
L-cysteine is unstable in its free form — it oxidises rapidly in the digestive system and bloodstream, converting to L-cystine before it can be utilised. This instability is precisely the problem RiboCeine was designed to overcome.
The Ribose Bond
D-ribose, a naturally occurring pentose sugar involved in ATP and nucleotide synthesis, forms a stable glycosidic bond with cysteine. This bond protects cysteine from oxidation while simultaneously facilitating cellular uptake via nucleoside transporters.
Intracellular Release
Once inside the cell, cytoplasmic conditions trigger the controlled release of cysteine from the ribose carrier. The cell then uses gamma-glutamylcysteine synthetase (the primary rate-limiting enzyme in glutathione synthesis) to produce GSH in exactly the quantity the cell can use.
UNISUL CLINICAL TRIAL &�iddot; PROTOCOL #6.597.558 · 2023
The Clinical Trial: Full Results
A double-blind, placebo-controlled, randomised clinical trial conducted at the University of Southern Santa Catarina (UNISUL), Brazil. Approved by the institutional Ethics Committee. Published 2023.
Study Methodology
Results at 28 Days
-3.2%
Placebo Group
Ages 35–60 · 28 days
Even healthy adults without supplementation experienced a measurable decline in glutathione over the 28-day period. This confirms the constant oxidative drain on glutathione reserves in normal daily life.
+26.6%
RiboCeine Group
Ages 35–60 · 28 days
Average increase across all adult participants in the active arm. In healthy, non-depleted adults, a 26.6% increase in glutathione in four weeks represents a substantial cellular change.
+64.7%
RiboCeine Group
Ages 51–60 · 28 days
The most remarkable finding: older participants showed dramatically greater response. This is consistent with the theory that individuals with more depleted baseline levels have greater capacity for restoration. Those who need it most benefit most.
Why These Results Matter
Healthy Adults, Not Patients
Most supplement trials use participants with known deficiencies or medical conditions — where any effect is magnified. The UNISUL trial used healthy adults. A 26.6% increase in people who were already healthy demonstrates a powerful baseline effect, not just a correction of deficiency.
Double-Blind Design
Neither participants nor researchers knew who received the active compound versus placebo during the trial. This eliminates placebo effect and researcher bias — the two most common sources of inflated results in supplement research. The results cannot be attributed to expectation.
Age-Stratified Results
The fact that participants aged 51–60 showed 64.7% increases versus 26.6% average across all ages is scientifically significant. It aligns precisely with the known age-related decline in glutathione production — older participants have more depleted cells that respond more dramatically to restored Cysteine availability.
Placebo Decline Confirms Oxidative Load
The -3.2% decline in the placebo group over just 28 days quantifies the ongoing oxidative depletion your body experiences in normal daily life. At that rate of decline, the cumulative loss over years and decades becomes substantial. RiboCeine does not merely slow this decline — it reverses it.
Healthy adults only. Results shown are from the UNISUL 2023 clinical trial. Individual results may vary. Cellgevity does not claim to treat, cure, or prevent any medical condition.
PUBMED · US GOVERNMENT MEDICAL LIBRARY
The Most Researched Antioxidant in Medical History
Glutathione is not a fringe wellness trend. It is the most studied antioxidant molecule in biomedical research — with over 200,000 peer-reviewed citations on the US Government's official medical research database.
Glutathione vs. Other Antioxidants: Research Volume
Source: PubMed.ncbi.nlm.nih.gov. Data as at 20 January 2026.
A Molecule at the Centre of Medical Science
Glutathione first isolated by J. de Rey-Pailhade. Its significance was not yet understood.
Frederick Gowland Hopkins identifies the tripeptide structure. Research into its biological role begins in earnest.
Dr. Nagasawa begins his research at the University of Minnesota into cysteine delivery and intracellular glutathione biosynthesis.
Glutathione’s role in immune function, detoxification, and mitochondrial health becomes established in peer-reviewed literature.
US Patent No. US 8,501,700 B2 granted for RiboCeine (D-ribose-L-cysteine). Cellgevity launched commercially.
UNISUL publishes the first double-blind, placebo-controlled trial of RiboCeine. +64.7% glutathione in 28 days confirmed.
See the Science Explained
A detailed explanation of the RiboCeine mechanism, the science of glutathione, and why intracellular production is the only approach that works.
The evidence is publicly available. Every claim on this page can be verified independently on PubMed — the US Government’s official medical research database, maintained by the National Institutes of Health.
Search PubMed for glutathione research →START YOUR CELLULAR HEALTH JOURNEY
The Research Is Clear. The Results Are Documented.
40 years of research. 185 published studies. One clinical trial showing a 64.7% increase in 28 days. If you have read this far, you understand the science. The next step is experiencing it.